Stockwinners Market Radar for May 26, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:10 EDT Royal Caribbean gets approval to resume U.S. sailings in June - The company states: "Royal Caribbean has received approval to resume sailings from the United States after more than a year of suspended operations during the COVID-19 pandemic. On June 26, the cruise company will mark a long-awaited return with Celebrity Cruises' Celebrity Edge departing from Port Everglades in Fort Lauderdale. All sailings will depart with vaccinated crew and everyone over the age of 16 must present proof of vaccination against COVID-19; as of August 1, 2021, all guests ages 12 and older must present proof of vaccination."

19:56 EDT Xencor's Xtend technology gets emergency use authorization from FDA - Xencor "announced that the FDA has granted an emergency use authorization for sotrovimab, an XmAb-engineered antibody developed by Vir Biotechnology, Inc. (Vir) and GlaxoSmithKline plc (GSK). Sotrovimab has not been approved, but has been authorized for emergency use by the FDA under an EUA, to treat mild-to-moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Xencor has provided Vir non-exclusive licenses to XmAb Fc technologies, including Xtend(TM), designed to enhance the half-life of novel antibodies being investigated as potential treatments for patients with COVID-19."

19:12 EDT Datadog CFO sells 20K shares of common stock - In a regulatory filing, Datadog disclosed that its CFO David Obstler sold 20K shares of common stock on May 24th in a total transaction size of $1.8M, reducing his stake by about 8%.

18:58 EDT GSK, Vir confirm sotrovimab receives EUA from FDA - GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) announced the U.S. Food and Drug Administration granted an Emergency Use Authorization for sotrovimab, an investigational single-dose monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Adrienne E. Shapiro, M.D., Ph.D., an infectious disease specialist at Fred Hutchinson Cancer Research Center and investigator in the COMET-ICE trial, said: "Monoclonal antibodies like sotrovimab are potentially one of our most effective tools for fighting COVID-19. While preventive measures, including vaccines, can reduce the total number of cases, sotrovimab is an important treatment option for those who become ill with COVID-19 and are at high risk - allowing them to avoid hospitalization or worse."

18:49 EDT Switch CEO Roy sells 100,000 class A shares - In a regulatory filing, Switch CEO Rob Roy disclosed the sale of 100,000 class A common shares of the company on May 24 at a price of $19.0753 per share.

18:47 EDT FDA issues EUA for Vir and GSK's COVID-19 antibody therapy - The U.S. Food and Drug Administration issued an emergency use authorization for the investigational monoclonal antibody therapy sotrovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death. This includes, for example, individuals who are 65 years of age and older or individuals who have certain medical conditions. The safety and effectiveness of this investigational therapy continues to be evaluated for treatment of COVID-19. Sotrovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. This treatment has not shown benefit in patients hospitalized due to COVID-19 and monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients requiring high flow oxygen or mechanical ventilation. The EUA was issued to GlaxoSmithKline (GSK). The Fly notes that Vir Biotechnology (VIR) also worked on the antibody therapy. Reference Link

18:03 EDT Kroger associates in Cincinnati, Dayton, and Kentucky ratify labor agreement - Kroger's Cincinnati-Dayton division and United Food and Commercial Workers Union Local 75 members in Cincinnati, Dayton, Northern Kentucky, and Southeastern Indiana ratified a new labor agreement. The Cincinnati-Dayton division is investing $159M in wages across the five-year agreement.

17:49 EDT Citizens to acquire East Coast branches, online deposit business from HSBC - Citizens Financial Group (CFG) announced that Citizens Bank, N.A. has entered into an agreement to acquire 80 East Coast branches and the national online deposit business from HSBC Bank U.S.A (HSBC). Under the agreement, Citizens will acquire approximately $9B in deposits and approximately $2.2B in loans for a 2% premium paid on deposits at closing. The transaction is expected to be immediately accretive to Citizens' earnings per share and generate an internal rate of return of approximately 20%. "This transaction provides us with an attractive entry into the important New York City Metro, Washington D.C. and Southeast Florida markets," said Chairman and CEO Bruce Van Saun. "With a sizable customer base and a solid expansion strategy. In addition, the $7 billion net deposit position provides us sigdeposit franchise, this acquisition will serve as a springboard for our consumer national nificant long-term funding flexibility in support of our attractive loan growth opportunities." The 80 branch purchase includes 66 locations in the New York City Metro area, 9 locations in the Mid-Atlantic/Washington D.C. area, and 5 locations in Southeast Florida. The branches to be acquired will operate as HSBC branches until closing and will be re-branded as Citizens branches immediately upon closing of the transaction. This transaction is expected to close in the first quarter of 2022, subject to customary closing terms and conditions and regulatory approvals.

17:47 EDT Schrodinger holder David Shaw sells 74.1K shares of common stock - In a regulatory filing, Schrodinger disclosed that David E. Shaw sold 74.1K shares of common stock on May 24th in a total transaction value of $4.98M, reducing his stake by about 1%.

17:33 EDT CME Group announces micro bitcoin futures volume top 500K contracts - The company "announced that Micro Bitcoin futures volume surpassed 500,000 contracts on Monday, May 24." Tim McCourt, CME Group Global Head of Equity Index and Alternative Investment Products, says: "We are pleased with the strong uptake and support we have seen for this new contract so early on in its first month. At one-fiftieth the size of our larger Bitcoin futures, this new, smaller contract allows traders of all sizes to better manage their bitcoin price risk in an efficient, cost-effective way."

17:29 EDT Nvidia sees sequential growth in Q2 Data Center revenue - Sees Q2 non-GAAP gross margin 66%-67%.

17:18 EDT Select Medical director Cressey sells $399K in shares - Select Medical director Bryan Cressey disclosed in a filing that he had sold 10,000 shares of company stock at $39.90 per share on May 24, for a total transaction amount of $399,000.

17:18 EDT Nvidia CFO says saw strong results with Mellanox products

17:16 EDT Point72 Asset Management reports passive stake in Aerpio Pharmaceuticals - Point72 Asset Management and Point72 Capital Advisors each disclosed a 3.9% stake in Aerpio Pharmaceuticals, which represents 1.825M shares each. The filing does not allow for activism.

17:09 EDT TSR reports final court order approving stockholder derivative action settlement - TSR announced that the Supreme Court of the State of New York, Queens County issued a final order and judgment approving the settlement in the stockholder class and derivative action captioned Susan Paskowitz v. James J. Hill et al., filed by Susan Paskowitz, a stockholder of the company, on October 16, 2018. On December 16, 2019, the company entered into a stipulation and agreement of settlement with Susan Paskowitz providing for the settlement of the stockholder action. The court entered an order preliminarily approving the settlement. Pursuant to the terms of the final order, the court fully and finally approved the settlement set forth in the stipulation and dismissed the stockholder action with prejudice. The settlement payment is expected to be paid by the company's insurance provider under its insurance policy.

17:04 EDT Nvidia says to remain supply-constrained into second half of the year - Comments taken from Q1 earnings conference call.

17:01 EDT Potbelly names Larry Strain chief development officer - Potbelly Corporation announced the appointment of Larry Strain as its Chief Development Officer effective immediately. Potbelly is contracting with Restaurant Development Experts, LLC in connection with Strain's engagement for this role and Bob Wright, President and Chief Executive Officer of Potbelly, will have oversight responsibility for him in this leadership position. Strain will oversee four key areas of shop development including Corporate Development Services, Franchise Sales & Development, Brokerage Services & Tenant Representation, and Strategic & Trade Area Level Market Planning. Bob Wright, President and Chief Executive Officer of Potbelly commented, "The addition of Larry and his wealth of experience in real estate and franchise development is critical in advancing Potbelly to our next phase of growth. Larry is a highly regarded retail development and business strategist with the necessary background to advance Potbelly in the next stage of our 'Traffic-Driven' Profitability Strategic Plan. I could not be more excited to welcome him to our executive team."

16:57 EDT 23andMe to trade on Nasdaq as 'ME' - VG Acquisition Corp. announced that, upon the Domestication and the consummation of its pending business combination with 23andMe, Inc., New 23andMe Class A Common Stock and New 23andMe Warrants will be listed on The Nasdaq Global Select Market. The decision to list on Nasdaq was made in connection with the Business Combination and enables the combined company to be listed alongside other innovative companies that are also listed on Nasdaq. Prior to the consummation of the Business Combination, VGAC will domesticate as a Delaware corporation and will change its name to "23andMe Holding Co." In connection with the Domestication, each of the then issued and outstanding VGAC Class A ordinary shares, par value $0.0001 per share, and each issued and outstanding VGAC Class B ordinary share, par value $0.0001 per share, will convert automatically, on a one-for-one basis, into a share of Class A common stock, par value $0.0001 per share, of New 23andMe; each of the then issued and outstanding whole warrants to purchase Class A ordinary shares of VGAC will automatically represent the right to purchase one share of New 23andMe Class A Common Stock at an exercise price of $11.50 per share on the terms and conditions set forth in the warrant agreement, dated October 1, 2020, between VGAC and Continental Stock Transfer & Trust Company, as warrant agent; and each of the then issued and outstanding units of VGAC that has not been previously separated into the underlying VGAC Class A Ordinary Shares and the underlying warrants of VGAC prior to the Domestication will be canceled and will entitle the holder thereof to one share of New 23andMe Class A Common Stock and one-third of one warrant representing the right to purchase one share of New 23andMe Class A Common Stock at an exercise price of $11.50 per share on the terms and subject to the conditions set forth in the VGAC Warrant Agreement. Trading is expected to begin on Nasdaq on June 17, 2021, under the new ticker symbol "ME" for the New 23andMe Class A Common Stock and "MEUSW" for the New 23andMe Warrants, following the consummation of the Business Combination, which is currently expected to occur on June 16, 2021, subject to final shareholder approval at VGAC's extraordinary general meeting on June 10, 2021, and satisfaction of other customary closing conditions. Until the Domestication and transfer to Nasdaq is complete, the VGAC Class A Ordinary Shares, warrants, and units will continue to trade under the ticker symbols "VGAC,""VGAC.WS," and "VGAC.U," respectively, on the New York Stock Exchange. The last day of trading on the NYSE is expected to be on June 16, 2021.

16:40 EDT Superior Drilling receives noncompliance notification from NYSE - Superior Drilling announced that the company received notification from the NYSE that it had not met compliance standards of Section 1003 as a result of stockholders' equity falling below $4M and having reported losses in its five most recent fiscal years ended December 31, 2020. Stockholders' equity was approximately $3.3M as of March 31.

16:30 EDT Intelligent Systems receives approval to list its stock on NYSE - On May 26, Intelligent Systems announced that it has received approval to list its common stock, par value $0.01 per share on the New York Stock Exchange. The Company provided written notice on May 26 to the NYSE American of its intention to list its Common Stock on the NYSE and to simultaneously delist such securities from the NYSE American. The Company anticipates that its Common Stock will begin trading on the NYSE at the commencement of trading on June 2, 2021 under the symbol "INS", and that until the close of trading on June 1, 2021, the Common Stock will continue to trade on the NYSE American under the symbol "INS." The Company's Board of Directors has approved the transfer to the NYSE.

16:21 EDT FDA approves Myovant's and Pfizer's MYFEMBREE for heavy menstrual bleeding - Myovant Sciences (MYOV) and Pfizer (PFE) announced that the U.S. Food and Drug Administration, FDA, has approved MYFEMBREE, for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months. The approval is supported by efficacy and safety data from the Phase 3 LIBERTY 1 and LIBERTY 2 studies, which were published in the New England Journal of Medicine. Under the terms of their previously announced collaboration, Myovant and Pfizer will jointly commercialize MYFEMBREE in the U.S. MYFEMBREE is expected to be available in June 2021.

16:19 EDT American Eagle reports Q1 total inventory at $467M, up 2% vs. 2019 levels - The company states its "digital momentum continued with revenue up 57% including Aerie up 158% and AE up 20%"

16:17 EDT Universal Corporation raises annual dividend to $3.12 per common share - George Freeman, III, Chairman, President, and CEO of Universal Corporation, announced that the company's Board of Directors declared a quarterly dividend of 78c per share on the common shares of the company, payable August 2 to common shareholders of record at the close of business on July 12. This increase indicates an annualized rate of $3.12 per common share and a yield of approximately 5% based on the $59.06 closing price on May 25.

16:15 EDT Qad Inc. sees Q2 subscription revenue $38.5M, maintenance revenue $26M

16:10 EDT Okta CFO Mike Kourey stepping down, Brett Tighe named interim CFO - Okta announced today that Mike Kourey is stepping down from his position as Chief Financial Officer, effective June 1. Kourey will sign the quarterly report and will remain at Okta in an advisory role. Brett Tighe, Okta's Senior Vice President of Finance and Treasurer, has been appointed as interim CFO while the Company conducts a search for a permanent replacement. Tighe has been with Okta for the past six years.

16:08 EDT Pure Storage reports Q1 adjusted gross margin 70.5%

16:04 EDT Okta reports Q1 Remaining Performance Obligations up 52% at $1.89B - Q1 total calculated billings were $364 million, an increase of 74% year-over-year.

16:03 EDT Ironwood to partner with Teva on LINZESS prior to patent expiration - The company states: "Ironwood Pharmaceuticals (IRWD), announced that, with its partner AbbVie (ABBV), the companies have reached an agreement with Teva Pharmaceuticals USA (TEVA) providing a license to Teva's abbreviated new drug application seeking approval to market a generic version of 72 mcg LINZESS prior to the expiration of the companies' applicable patents. With this agreement, the companies have settled with the filers of all known ANDAs to date seeking approval to market generic versions of LINZESS. Pursuant to the terms of the agreement, Teva will be granted a license to market its 72 mcg generic version of LINZESS in the United States beginning March 31, 2029, subject to U.S. FDA approval, unless certain limited circumstances, customary for settlement agreements of this nature, occur. Previously, Ironwood and Allergan granted Teva a license to market its 145 mcg and 290 mcg generic versions of LINZESS in the United States beginning on the same date. That grant was in connection with a settlement resolving all previous Hatch-Waxman litigation between the companies and Teva regarding LINZESS patents pending in the U.S. District Court for the District of Delaware. Additional details regarding the settlements were not disclosed."

15:42 EDT Donaldson increases quarterly dividend 4.8% - Donaldson Company announced that its board declared a regular cash dividend of 22c per share, an increase of 4.8% from the prior quarterly cash dividend of 21c per share. The dividend is payable June 25 to shareholders of record on June 10.

15:21 EDT Microsoft says Xbox & Bethesda Games showcase to stream June 13 - Microsoft announced the Xbox & Bethesda Games Showcase will stream on Sunday, June 13 at 10:00 a.m. PT. The show will be focused on games from Xbox Game Studios, Bethesda, and many game creators from Microsoft partners around the world. "You've told us how excited you are about welcoming Bethesda into the Xbox family, so we know you're going to want a front-row seat to the Xbox & Bethesda Games showcase - a 90-minute show packed with everything you want to know about the epic gaming lineup coming out of this partnership, the incredible games coming to Xbox this holiday, upcoming releases on Xbox Game Pass, and more," Microsoft said.

15:07 EDT Myovant Sciences' Myfembree granted priority approval by FDA - A post to the FDA website indicates that Myovant Sciences' New Drug Application, or NDA, number 214846 for Myfembree was granted approval with an action date of Mayr 26. Myovant shares are up 3% to $23.54 in afternoon trading. Reference Link

14:45 EDT Lizhi up $2.92, or 67%, to $7.26 in afternoon trading

14:34 EDT Icahn says Allstate doing right things, a 'great company'

14:31 EDT Icahn confirms holding stake in Allstate, which he calls 'great company' - Carl Icahn, CEO of Icahn Capital, is being interviewed on Bloomberg Television and confirmed that he holds a stake in Allstate (ALL), as reported by The Wall Street Journal.

14:26 EDT Santiago Exchange suspends Latam Airlines trading after sale report denial - Jerome Cadier, head of LatamBrasil, told local newspaper Valor Economico that Latam Airlines (LTMAQ) is not considering a sale of its Brazilian operations, according to Bloomberg. The paper and Reuters reported earlier that Azul (AZUL) was in talks with aircraft leasing companies to prepare a bid for Latam Brazil. Trading in Latam Airlines shares was suspended on the Santiago Exchange after the shares dropped as much as 21.5% today. The stock in afternoon trading is down 8% to $2.74 in the U.S.

14:20 EDT Fluor says IHI is investing $20M in NuScale Power - Fluor announced that IHI Corporation of Japan is investing $20M into NuScale Power, a small modular nuclear reactor technology company in which Fluor is the majority investor. IHI's immediate investment of $20M may be followed by another $20M later, the company said. In addition to IHI's ownership interest, IHI will become a manufacturing partner and have the opportunity to provide design services and heavy manufacturing of the steel plate reinforced concrete wall structures for NuScale SMR projects in which Fluor has the lead role, it added.

14:16 EDT Icahn says renewable fuels 'here to stay,' climate change an 'interesting area' - Carl Icahn, CEO of Icahn Capital, is being interviewed on Bloomberg Television about activism in general and the activist shareholder that won seats on Exxon Mobil's (XOM) in particular.

13:50 EDT CURE commends Exxon Mobil shareholders for electing Engine No. 1 candidates - The Coalition United for a Responsible Exxo that recently published a paper that analyzes ExxonMobil Corporation's critical governance failures and poor performance sees the election of Gregory Goff and Kaisa Hietala to the board of directors as significant steps towards the transformation outlined in the CURE report. "Today, shareholders sent a strong signal to Exxon and other oil majors that business as usual is not an option," said Andrew Behar, CEO of As You Sow, a member of CURE. "The fact that at least two of Engine #1's four board candidates were elected reflects the right of shareholders to escalate the demand for transformation at companies such as Exxon. The new board should act on this mandate for change and adopt Paris compliant transition plans immediately and begin the hard, but necessary work of creating the roadmap to transform the company's core business."

13:33 EDT North American rail traffic rose 22.4% in week ended May 22, AAR says - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending May 22. For this week, total U.S. weekly rail traffic was 528,774 carloads and intermodal units, up 23.4% compared with the same week last year. Total carloads for the week ending May 22 were 242,227 carloads, up 27.2% compared with the same week in 2020, while U.S. weekly intermodal volume was 286,547 containers and trailers, up 20.4% compared to 2020. For some rail traffic categories, percentage changes for the current week compared with the same week in 2020 are inflated because of the widespread shutdowns - and subsequent large reduction in rail volumes - that impacted many economic sectors last year at this time. North American rail volume for the week ending May 22, on 12 reporting U.S., Canadian and Mexican railroads totaled 340,793 carloads, up 24.6% compared with the same week last year, and 378,724 intermodal units, up 20.4% compared with last year. Total combined weekly rail traffic in North America was 719,517 carloads and intermodal units, up 22.4%. North American rail volume for the first 20 weeks of 2021 was 14,010,375 carloads and intermodal units, up 11.4% compared with 2020. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Genesee & Wyoming (GWR), Kansas City Southern (KSU), Norfolk Southern (NSC) and Union Pacific (UNP).

13:16 EDT Facebook says taking action against people who repeatedly share misinformation - Facebook said in a post to its corporate site: "Today, we're launching new ways to inform people if they're interacting with content that's been rated by a fact-checker as well as taking stronger action against people who repeatedly share misinformation on Facebook. Whether it's false or misleading content about COVID-19 and vaccines, climate change, elections or other topics, we're making sure fewer people see misinformation on our apps." Reference Link

12:55 EDT Bayer falls after judge denies plan to resolve future Roundup lawsuits - Shares of Bayer after lower after Bloomberg's Joel Rosenblatt reported that U.S. District Judge Vince Chhabria issued an order denying preliminary approval of the company's plan to pay as much as $2B to resolve future lawsuits over claims that its Roundup weed killer causes cancer. Shares of Bayer are down 3% to $16.39 in afternoon trading.

12:30 EDT Facebook to roll out option to hide public like counts - Facebook announced that everyone on Instagram and Facebook will now have the option to hide their public like counts, so they can decide what works for them. "Starting today, we're giving you the option to hide like counts on all posts in your feed," the company said in a blog post. "You'll also have the option to hide like counts on your own posts, so others can't see how many likes your posts get. This way, if you like, you can focus on the photos and videos being shared, instead of how many likes posts get. You can hide like counts on others' posts by visiting the new Posts section in Settings. This control applies to all the posts in your feed. You can also choose to hide like counts before sharing a post. You can turn this setting on or off, even after it goes live. People want more flexibility, so we thought it would be important to give people the option. In the next few weeks you will see both of these controls come to Facebook." Reference Link

12:12 EDT Caesars announces William Hill Sportsbook opens at Capital One Arena - The William Hill Sportsbook at Monumental Sports & Entertainment's Capital One Arena officially opened today, "becoming the first ever sports betting venue to open within a U.S. professional sports facility," announced Caesars Entertainment. The company said: "William Hill, a part of Caesars Entertainment, and Monumental Sports & Entertainment announced a groundbreaking partnership deal in October 2019 to open the first-of-its-kind, marquee destination for local, regional and global visitors... The William Hill Sportsbook at Monumental Sports & Entertainment's Capital One Arena is the first-of-its-kind and is operated by Caesars Entertainment. Caesars Entertainment recently completed its acquisition of William Hill, PLC and currently offers sports betting options in 18 U.S. states and territories, including over 170 retail sportsbooks."

12:00 EDT Nordstrom falls -8.0% - Nordstrom is down -8.0%, or -$2.92 to $33.56.

12:00 EDT AMC Entertainment rises 17.3% - AMC Entertainment is up 17.3%, or $2.84 to $19.25.

12:00 EDT Express rises 28.2% - Express is up 28.2%, or $1.11 to $5.05.

11:50 EDT Engine No.1 calls Exxon Mobil delay 'attempt to entrench board' - Engine No. 1, which has nominated four director candidates to the Exxon Mobil Corporation Board of Directors in connection with the 2021 Annual Meeting of Shareholders, today issued the following statement: "In seeking to delay the closing of the polls, ExxonMobil is using corporate machinery for its own purpose rather than that of shareholders and avoiding the election of individuals with the transformative energy experience required to position the Company for long-term success in a changing world. Shareholders should not be fooled by ExxonMobil's last-ditch attempt to stave off much-needed board change in response to significant shareholder pressure and the prospect of losing a proxy contest. Shareholders have spoken. ExxonMobil should accept the result, take the vote and move forward."

11:39 EDT Lockheed Martin, GM to develop next-generation lunar rover for NASA - Lockheed Martin (LMT) and General Motors (GM) announced they are teaming up to develop the next generation of lunar vehicles to transport astronauts on the surface of the Moon, "fundamentally evolving and expanding humanity's deep-space exploration footprint." The companies said: "NASA sought industry approaches to develop a Lunar Terrain Vehicle (LTV) that will enable astronauts to explore the lunar surface farther than ever before. The LTV is the first of many types of surface mobility vehicles needed for NASA's Artemis program. To support NASA's mission, the two industry leaders will develop a unique vehicle with innovative capabilities, drawing on their unparalleled engineering, performance, technology and reliability legacies. The result may allow astronauts to explore the lunar surface in unprecedented fashion and support discovery in places where humans have never gone before. Lockheed Martin will lead the team by leveraging its more than 50-year-history of working with NASA on deep-space human and robotic spacecraft, such as NASA's Orion exploration-class spaceship for Artemis and numerous Mars and planetary spacecraft."

11:36 EDT Panini America, Funko announces Funko Pop! Trading Card line - Panini America and Funko announced a new Pop! product line, Funko Pop! Trading Card that will extend across multiple sports later this year. The initial series will feature six NBA players and six NFL players and will hit retail shelves in time for the holiday shopping season. The introduction of Funko Pop! Trading Card will incorporate Panini's globally popular Prizm trading card brand for both the NBA and NFL. Similar to the very popular Pop! Albums and Pop! Comic Covers, Pop! Trading Card will feature the Panini Prizm trading card art packaged together in a protective case that can be hung on a wall. The Pop! Vinyl figure will replicate the poses from the player imagery from their respective Prizm trading cards.

11:28 EDT Intercept down 57c, or 4%, to $14.89 after FDA adds warnings for Ocaliva in PBC

11:25 EDT FDA restricts use of Intercept's Ocaliva in PBC patients with advanced cirrhosis

11:01 EDT Astec launches rebrand to simplify business - Astec Industries is launching a new modern look with a rebranding initiative to coincide with its business model. The rebrand includes a new logo, color palette and website. The launch comes while the organization streamlines its internal structure and operations to improve efficiency and drive growth. The organization's former brands, including Astec Inc., Astec do Brasil, Astec Australia, BMH Systems, Breaker Technology, Carlson Paving, Con-E-Co, Heatec, KPI-JCI and Astec Mobile Screens, Osborn, Peterson, RexCon, Roadtec and Telsmith, will no longer operate as separate subsidiary companies and will all take on the ASTEC name. The unification is a significant part of the company's OneASTEC business model including its "Simplify, Focus and Grow" strategy.

10:55 EDT WarnerMedia says HBO Max coming to 39 Latin American territories on June 29 - HBO Max, the WarnerMedia subscription streaming platform, announced that it will be available in 39 territories in Latin America and the Caribbean starting June 29. "Our launch in Latin America and the Caribbean is the first step in our global rollout of HBO Max. We are thrilled that fans across the region will soon be able to enjoy HBO Max and its amazing collection of content. WarnerMedia is one of the most popular and trusted sources of entertainment across Latin America, and we are very excited that our global journey starts here," commented Johannes Larcher, Head of HBO Max International. AT&T (T) and Discovery (DISCA) recently announced a definitive agreement to combine WarnerMedia's assets with Discovery's businesses to create a standalone global entertainment company.

10:37 EDT GameStop hiring team to build NFT platform - GameStop is hiring a team to develop its own non-fungible token, or NFT, platform, according to a website set up by the company. The company, which also posted a link to an Ethereum address, said, "We are building a team. We welcome exceptional engineers, designers, gamers, marketers, and community leaders." Reference Link

10:18 EDT Wrap Technologies: Seattle PD approves BolaWrap pilot program - Wrap Technologies announced the Seattle Police Department has approved a pilot program for the BolaWrap Remote Restraint device. According to KOMO News in Seattle, SPD Interim Chief Adrian Diaz has greenlit the BolaWrap for field testing by the Seattle Police Department. More details will be released about the program when available, the company said in a statement. Tom Smith, President and CEO of WRAP, said, "Our team looks forward to working with the Seattle Police Department to support successful implementation of the BolaWrap and training that best fits their needs for innovative public safety and law enforcement solutions focused on avoiding escalation of force."

10:03 EDT Polaris names Chris Wolf as chief product excellence, quality, safety officer - Polaris announced that Chris Wolf has been named to the role of chief product excellence, quality and safety officer. Polaris initiated a search for this newly elevated role after Todd Gross, vice president of Global Product Safety and Quality, shared his intent to retire earlier this year. Wolf, who has been with the company for nearly 20 years, most recently served as president of Snowmobiles. Wolf will lead the Global Product Safety and Quality team and continue to serve as a member of the company's executive leadership team, reporting to Ken Pucel, executive vice president of Global Operations, Engineering and Lean. John Stockman has been named vice president and general manager of Snow, reporting to Steve Menneto, president of Off Road. Stockman will succeed Wolf in leading the company's Snow business, including product development, engineering, marketing and sales. He has been with the company for more than six years, most recently as vice president of Strategic Initiatives, Corporate Partnerships and Boats Integration.

10:00 EDT RLX Technology falls -11.7% - RLX Technology is down -11.7%, or -$1.29 to $9.73.

10:00 EDT Dick's Sporting rises 11.7% - Dick's Sporting is up 11.7%, or $9.87 to $94.04.

10:00 EDT Owens & Minor rises 13.6% - Owens & Minor is up 13.6%, or $4.41 to $36.81.

09:50 EDT Velodyne Lidar calls assertions by David Hall, Marta Thoma Hall 'baseless' - Velodyne Lidar issued a response to a filing by David Hall and Marta Thoma Hall and Eric Singer. The response read in part, " Velodyne Lidar is the leading lidar company, known worldwide for its broad portfolio of breakthrough lidar technologies, having delivered approximately $95 million in revenue through the sale of 11,710 units in 2020. The Velodyne Lidar Board of Directors and management team are executing on a strategy designed to drive long-term growth for the Company and value for stockholders with the highest standards of corporate governance. Under the direction of the current Board, the Company continues to set production records and the management team is delivering significant progress on its growth plans, positioning Velodyne Lidar to meet the rapidly growing volume requirements of its customers in the coming years. Today, Velodyne Lidar is the only lidar company with both the breadth of product portfolio and the manufacturing capability to deliver low-priced lidar with multiple specifications at scale for many real-world applications. Velodyne Lidar also continues to innovate, launching award-winning products that will continue to advance the Company's strong pipeline and meet the increased demand for its revolutionary hardware and software solutions. The Company believes its pipeline is the most robust in the industry, as demonstrated by a 51% increase in projects - growing from 131 projects in January 2020 to 198 as of May 2021. Velodyne Lidar shipped over 2,600 sensors in the first quarter of 2021 alone, including 600 solid state sensors. Based on available public information, this far exceeded shipments of all of the Company's public competitors combined. ..As disclosed on February 22, 2021, the Board's independent Audit Committee conducted an investigation, aided by independent legal counsel, which concluded that Mr. and Mrs. Hall each behaved inappropriately with regard to Board and Company processes, and failed to operate with respect, honesty, integrity, and candor in their dealings with Company officers and directors. Accordingly, the Board approved remedial actions including censure and the removal of Mr. Hall as Chairman of the Board and the termination of Ms. Hall as an employee of the Company...The Velodyne Lidar Board prides itself on its commitment and adherence to sound corporate governance, seeking highly qualified, independent and diverse directors. The Halls have put forward a candidate in Eric Singer who the Board believes exemplifies none of those characteristics. The Board determined not to recommend Mr. Singer for election at the upcoming Annual Meeting of Stockholders following a comprehensive process to evaluate Mr. Singer, including reviewing his qualifications and prior experience...Velodyne's Board of Directors recommends stockholders support Mr. Zarringhalam's nomination at the 2021 Annual Meeting of Stockholders. There are two Class I seats up for election at the Company's 2021 Annual Meeting of Stockholders and, for one of them, the Board has nominated and recommended Mr. Zarringhalam. The Board does not recommend any candidate for election other than Mr. Zarringhalam. "

09:48 EDT Nordstrom falls -9.6% - Nordstrom is down -9.6%, or -$3.51 to $32.97.

09:47 EDT GSX Techedu falls -16.5% - GSX Techedu is down -16.5%, or -$3.30 to $16.65.

09:47 EDT GameStop rises 10.9% - GameStop is up 10.9%, or $22.81 to $232.24.

09:44 EDT Waldencast Acquisition Corporation (Class A Stock) trading resumes

09:42 EDT Supernova Partners Acquisition Company III Ltd (Class A Stock) trading resumes

09:41 EDT FTAC Parnassus Acquisition Corporation (Class A Stock) trading resumes

09:37 EDT CF Acquisition Corporation VIII (Class A Stock) trading halted, volatility trading pause

09:37 EDT LDH Growth Corporation I (Class A Stock) trading halted, volatility trading pause

09:36 EDT PAVmed's Lucid Diagnostics receives CE Mark certification for EsoCheck device - PAVmed and its major subsidiary Lucid Diagnostics announced that Lucid's EsoCheck Esophageal Cell Collection Device with Collect+Protect technology has received CE Mark certification. EU-based Notified Body TundefinedV Rhineland LGA Products GMBH issued a CE Certificate, effective May 24, 2021, declaring that EsoCheck conforms to the essential requirements of Medical Device Directive 93/42/EEC. With CE Mark secured, EsoCheck may now be marketed in CE Mark European countries, which include the European Economic Area, Switzerland, and, until July 1, 2023, the United Kingdom.

09:33 EDT CleanSpark finalizes purchase of ATL Data Center real estate - CleanSpark announced that it had completed the purchase of the six acre property which houses ATL Data Centers LLC and the 41,387 square foot data center building. As a part of the transaction in December of 2020, CleanSpark acquired the existing Bitcoin mining 'mobile data centers' within the facilities. The Company is in the process of expanding the number of mobile units deployed on-site in support of its focus on maximizing value and minimizing operating expense. A purchase option for the building and site was included in the original lease agreement at closing, and the resulting purchase transaction was finalized May 20, 2021 at a price of $4.71M. Obtaining ownership of the property will save the Company over fifty thousand dollars per month in rent resulting in a reduction of overhead and expenses by more than 20% in our mining segment. The Company will leverage the additional acreage to add renewables on site and to maximize the value of its substantial power purchase agreement.

09:30 EDT AIM ImmunoTech announces safety data from Phase 1 clinical trial on Ampligen - AIM ImmunoTech announced that it has completed dosing of Cohort 3 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting no serious adverse events. This is consistent with results in the first two cohorts of the study and at escalating doses. The study protocol called for a total of 40 healthy subjects to receive repeated administration of either Ampligen or a placebo. Subjects in Cohort 1 received 75 undefined of Ampligen, subjects in Cohort 2 received 200 undefined of Ampligen and subjects in Cohort 3 received 500 undefined. The study is already proceeding with Cohort 4, with subjects receiving 1250 undefined. The Centre for Human Drug Research, an independent institute located in Leiden in the Netherlands, is conducting the Phase 1 clinical study AMP-COV-100, titled "A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen in Healthy Subjects." AIM is sponsoring and funding the clinical study.

09:28 EDT Kymera Therapeutics presents new data on tissue-restricted E3 ligase - Kymera Therapeutics presented new data demonstrating proof-of-concept for its Pegasus platform, including the identification and characterization of a novel and previously unliganded E3 ligase with restricted expression in healthy tissues while broadly expressed in cancer cells, as determined by proteomics. Kymera discovered novel ligands for this ligase using state-of-the-art hit finding techniques and subsequently designed a novel proof-of-concept STAT3 degrader compound based on this novel E3 ligase. The degrader demonstrated potent and dose-dependent degradation of STAT3 across multiple cancer cell lines. These data are being presented by Chris De Savi, PhD, Vice President, Head of Drug Discovery at Kymera, today at the inaugural Ligase Targeting Drug Development Summit, taking place virtually from May 25-27. Kymera has identified the expression profiles of approximately 600 naturally-occurring unique E3 ligases across different tissues with its E3 Ligase Whole-Body Atlas. This knowledge enables Kymera to match a target protein with the appropriate E3 ligase based on expression, distribution, intracellular localization, and biology. Kymera has the ability to determine E3 ligase expression across both healthy and diseased tissues and can identify selective pairings of E3 ligases with therapeutic targets of interest, including tissue-selective or tissue-restrictive pairings. Kymera is building a proprietary toolbox of differentiated E3 ligase binders to enable the design of next-generation disease-specific degraders that target selective degradation in disease-relevant tissues, with the potential of sparing healthy tissues for an improved safety profile. Presentation highlights include: The abundance, characterization, and validation of novel chemical matter for a previously undrugged cullin-RING E3 ligase with ligandable domains and high 'ligandability' score; this novel E3 ligase is a tissue-restricted ligase, but is broadly expressed in multiple cancer cell lines; potent ligand binders identified using Pegasus platform, leading to design of degrader series across Kymera targets including proof-of-concept examples with IRAK4 and STAT3; and STAT3 degraders based on novel ligase demonstrate broad and potent degradation across multiple in vitro cancer cell lines.

09:19 EDT Vinci Partners Industrial Listed REIT announces deployment of capital raise - Vinci Partners Investments announced that Vinci Logistica FII, a listed REIT managed by Vinci Partners' Real Estate segment, committed to its final acquisition from the proceeds of the capital raise in March 2021. VILG is a perpetual capital listed REIT, focused on income generation to its quotaholders through the acquisition of industrial properties in Brazil. The fund currently has a market capitalization of over R$1.7B. Since the fund's last capital raise in March 2021, the management team has announced three acquisitions: a 50% stake in "Parque Logistico Pernambuco", located in Ipojuca, Pernambuco; 100% of "Porto Canoa LOG", located in Serra, Espirito Santo; and 100% of "Airport Town Guarulhos III", located in Guarulhos, Sao Paulo. All three assets are 100% leased to high-quality tenants.

09:18 EDT Verisk Analytics announces SmartScope feature for Xactimate, XactAnalysis - Property professionals can now save significant time estimating and managing water mitigation, interior and exterior claims with SmartScope, a new feature in Verisk's Xactimate and XactAnalysis solutions. The new SmartScope feature in Xactimate, powered by Vai, rapidly guides property professionals through the estimating and repair process for water mitigation, interior and exterior claims. Estimators simply answer dynamic questionnaires, apply line items, select property characteristics and then SmartScope automatically calculates repair costs. Water mitigation technicians can create floor plan diagrams, manage equipment placement and enter moisture readings from Xactimate mobile.

09:17 EDT Alkaline Water announces Caribbean distribution partnership with SaluVid - Alkaline Water announced its first Caribbean distribution partnership with SaluVid, a division of TraFon Group, who will market and promote the distribution and sales of the company's products throughout Puerto Rico and other select Caribbean islands.

09:15 EDT Veracyte announces XA can identify clinically relevant gene fusions - Veracyte announced new data that show the company's Afirma Xpression Atlas XA can identify clinically relevant gene fusions in thyroid nodule samples collected via fine needle aspiration, FNA. The findings, which will be presented June 4 at the 2021 American Society of Clinical Oncology ASCO Annual Meeting, support use of the whole transcriptome RNA-sequencing test to detect gene fusions that may guide the use of targeted treatments for thyroid cancer. "The increasing availability of targeted therapies for thyroid cancer, including tyrosine kinase inhibitors, means physicians must have tools that reliably identify the patients who may benefit from these therapies," said Lori J. Wirth, M.D., medical director of the Center for Head and Neck Cancers, Mass General Cancer Center, who will present the data. "Using the Afirma XA test, we were able to identify and report the prevalence of clinically relevant gene variants and fusions in real-world thyroid nodule samples." The American Cancer Society predicts that more than 44,000 individuals will be diagnosed with thyroid cancer in the United States this year. Pathologists use the Bethesda system to classify thyroid nodules into several categories - from benign to malignant - using FNA samples. The Afirma XA uses whole transcriptome RNA sequencing to identify 905 DNA variants and 235 RNA fusions in 593 genes on FNAs taken from thyroid nodules. Increasing numbers of these gene fusions can be targeted by small-molecule therapies.

09:11 EDT Nexstar names Courtney Williams as Chief Diversity Officer - Nexstar Media Group announced that it has named Courtney Williams to the newly created position of Chief Diversity Officer, responsible for leading the Company's efforts to expand diversity in hiring, promotion, and retention. Ms. Williams currently serves as Vice President of Human Resources for Nexstar. She will continue to report to Terri Bush, Senior Vice President of Human Resources and Associate Counsel, and assume her additional duties immediately. Ms. Williams joined Nexstar in late-2019, after serving in a variety of human resources leadership positions across a broad array of companies in different industries, including General Electric, Coca-Cola Refreshments, Gannett and Tribune Media. She was promoted to Vice President of Human Resources for Nexstar in September 2020, responsible for helping guide the Company's corporate management teams on all human resources issues, directing human resources staff, and optimizing the efficient delivery of corporate support to all employees on human resource matters. As Nexstar's Chief Diversity Officer, Ms. Williams will oversee the creation, development, and execution of a comprehensive strategic plan to expand the Company's diversity, equity, and inclusion efforts. She will also serve as the Chairperson of Nexstar's Diversity and Inclusion Council.

09:10 EDT TrueBlue loyalty program members able to earn American Airlines flight points - JetBlue (JBLU) and American Airlines (AAL) announced that JetBlue's TrueBlue loyalty program members are now eligible to earn points on all American Airlines-operated flights. The new accrual agreement covers American flights operating with the JetBlue code within the carriers' Northeast Alliance, as well as on all other American flights operating anywhere in the world. At the same time, American's AAdvantage members can now accrue miles on all JetBlue flights within and beyond the Northeast. "Just in time for summer travel, we're giving TrueBlue members more program value and versatility by offering the ability to earn TrueBlue points on thousands of daily flights operated by our Northeast Alliance partner, American Airlines," said Don Uselmann, vice president loyalty & personalization, JetBlue. "As JetBlue and American add more routes and new destinations to and from the Northeast, we're able to enhance our Northeast Alliance so that our loyal customers can get rewarded more often." "One of the best things about our Northeast Alliance is the additional benefits it brings to customers. This includes more ways to earn miles and more choice in how they use them, creating a truly valuable loyalty program," said Alison Taylor, American's chief customer officer. "Our partnership with JetBlue offers travelers more options to get to more places with ease, thanks to better schedules and on a more premium product."

09:08 EDT Association of Legal Administrators selects Progress Sitefinity Cloud - Progress announced that the Association of Legal Administrators has chosen Progress Sitefinity Cloud as its content management system. With Sitefinity Cloud content management system, ALA is able to build compelling digital experiences and transform the performance of its website through streamlining infrastructure maintenance.

09:08 EDT Advent Technologies reports Q1 RFB bookings, shipments up 500% - Advent Technologies reported that bookings and shipments of their materials for redox flow batteries, or RFBs, in Q1 rose by 500% year-over-year. Advent's materials apply to renewable energy storage and production, including the membrane electrode assemblies used in high temperature fuel cells. Emory DeCastro, Advent Technologies CTO, commented: "Advent's materials solve critical problems for flow batteries by making utility-scale energy storage devices cost effective. Our tremendous year-over-year increase not only represents the start of new supply agreements, but it is also our most significant contribution into commercial redox flow battery systems to date. The ability to provide increasing quantities of customer-specific components also reinforces our strategy of using Advent manufacturing processes at third party production facilities."

09:05 EDT Nokia, Proximus deploy Proximus live fiber network - Nokia (NOK) and Proximus (BAOGY) turned on "the world's fastest fiber access network" at a media event in Antwerp attended by the Belgian Minister of Telecommunications, the Mayor of Antwerp and executives and engineers from the two companies. Operating over existing fiber and Nokia equipment deployed in the Proximus network, the first ever 25G PON live network connects the Havenhuis building in the Port of Antwerp with the Proximus central office in the middle of the city. The network speed exceeded 20 Gigabits per second making it the fastest fiber network in the world.

09:04 EDT Cathie Wood's ARK Investment bought 245.3K shares of Twitter on Tuesday

09:03 EDT AVANGRID merger With PNM gets NRC approval - AVANGRID (AGR), a leading sustainable energy company, announced that it has received Nuclear Regulatory Commission, NRC, approval for its proposed PNM Resources (PNMR) merger. NRC approval represents the sixth governmental approval. The only remaining approval is from the New Mexico Public Regulation Commission, NMPRC.

09:02 EDT Insperity increases quarterly cash dividend 12.5% to 45c per share - Insperity announced that its board of directors has approved a 12.5% increase in its quarterly regular cash dividend from 40c to 45c per share. The cash dividend will be paid on June 24 to all stockholders of record as of June 10.

08:49 EDT Omniq receives $1.5M order for IoT 'contactless' data collection solution - OMNIQ announced that it has received purchase orders with a total value of approximately $1.5M from a leading freight transportation and logistics company which spans more than 40M square feet of warehousing space, across more than 150 locations with more than 10,000 employees. The purchase order is for rugged mobile computers to be used in DC operations conducting automation of processes, digital monitor and control and efficiencies through the supply chain level. "From the beginning of fiscal year 2021, we're experiencing a strong momentum that continues with this order from one of the largest freight transportation and logistics companies in the world and we are honored that OMNIQ was chosen to provide the technology and hardware to support its international supply chain operations," said Shai Lustgarten, CEO of OMNIQ. "Following the announced orders from different verticals like healthcare, retail, transportation and logistics, parking management and homeland security we leverage our very strong and loyal customer base that combined with the quality of our solutions form a strong base for future growth," concluded Lustgarten.

08:43 EDT Sabre partners with Byhours to distribute hotel microstays - Sabre and Byhours,an international platform for hotel microstays, have signed a new agreement to provide Sabre's agency community with relevant content that will allow them to sell rooms by the hour through the Byhours' Sabre Red App. Under the agreement, travel agents using Sabre's global distribution system will have access to Byhours' content. Headquartered in Barcelona, Spain, Byhours launched in 2012 and developed the first booking platform that offers hourly packages at hotels around the world, allowing customers to choose their check-in time, how long they want to stay, and pay only for the amount of time they need. In 2019, Byhours opened their second office in Mexico City as its operational hub for Latin America and the U.S.

08:41 EDT Evaxion Biotech appoints Lars Holtug to board of directors - Evaxion Biotech (EVAX) announced today its shareholders elected Lars Holtug as a member of its board of directors. The vote was held at Evaxion's Annual General Meeting on May 25. Lars Holtug will also chair Evaxion's Audit Committee, taking over from Helen Boudreau, who chose not to stand for re-election for personal reasons. Lars Holtug served for 35 years as an employee and partner of PwC in Denmark, including four years as chairman of the board. He currently serves on the boards of a number of companies, including Gaming Investment and MTI Caretag Invest, both of which as Chairman, and Ascendis Pharma (ASND) as a board member, Audit Committee Chair and member of the Remuneration Committee.

08:39 EDT Discovery CEO: Amazon-MGM deal boosts our value

08:38 EDT Repay and Paysafe team to enable U.S. merchants to accept online cash payments - Repay Holdings (RPAY) announced a partnership with Paysafe (PSFE), a leading specialized payments platform, to enable REPAY merchants to accept cash payments at over 60,000 of Paysafe's retail partner locations, including major convenience stores, dollar stores, and pharmacies across the United States. Leveraging Paysafe's Paysafecash online cash, or eCash, solution, these cash transactions are recorded as real-time payments, adding even greater convenience to payers and expanding the capabilities of lenders and B2C companies to meet customer payment preferences. The strategic partnership will complement REPAY's suite of electronic payment solutions by offering cash as an online payment option through Paysafecash, enabling businesses, particularly lenders, to accept cash in any U.S. retail location that accepts Paysafe's eCash product. Effectively, offering opportunities for payers to use eCash helps to bridge the gap between cash and online payments, particularly for the large number of unbanked and under-banked Americans today. Consumers initiate the online cash payment by selecting Paysafecash at checkout. They then receive a unique barcode, which gets scanned at the payment location and settled in cash. Once the cash transaction is complete, the payment is posted and REPAY delivers the transaction details back to the merchant, seamlessly updating the consumer's account with the most recent payment information. The money is subsequently deposited into the merchant's bank account via ACH - and is not subject to chargebacks as other electronic payments may be. "As REPAY continues to innovate, we aim to reduce the friction of the repayment process by offering convenient payment solutions for lenders and their borrowers," said Susan Perlmutter, Chief Revenue Officer, REPAY. "Through our partnership with Paysafe, lenders on the REPAY platform will be able to accept cash within the REPAY ecosystem through the Paysafecash eCash solution, benefiting from real-time posting and streamlined reconciliation processes. Consumers can now easily access any Paysafe retail partner location and quickly pay their bill."

08:36 EDT Discovery CEO 'happy' about Amazon deal to buy MGM

08:34 EDT Analog Devices expands BMS portfolio to enable continuous battery monitoring - Analog Devices announced its expanded portfolio of battery management system products including ASIL-D functional safety and innovative new low-power features to enable continuous battery monitoring. These new devices further differentiate ADI's BMS platform that today delivers the industry's best proven accuracy, and supports all key battery chemistries-including zero-Cobalt LFP for mass market electric vehicles and energy storage systems used for reuse and recycling of battery packs. Sales of full EVs continue to accelerate as consumers increasingly move to greener transportation and governments act to create a more sustainable future. Automakers are challenged to scale their EV fleets economically, while also staying ahead of evolving safety requirements across the world. Furthermore, to ensure maximum range per charge, the vehicle power consumption must be managed not only during driving, but also when the vehicle is parked. ADI's newest BMS products support multiple battery cell configurations and deliver innovative low-power features that enable the battery to be monitored continuously even when the vehicle is turned off to ensure safety under all conditions while maximizing vehicle range. "Collaborating with Analog Devices has allowed us to scale our electric vehicle range to meet increasingly strict regulations and the growing demands of today's EV owners," said Zhu Jun, General Manager of New Energy Business at SAIC. "These new BMS solutions will enable us to advance our commitment to safety and at the same time continue to make EVs accessible for mass market consumers." As EVs become mainstream in the market, requirements for BMS are growing. Receiving the ASIL-D rating signifies the new BMS solutions meet the highest possible standards for road vehicle functional safety required by regulatory agencies across the world.

08:32 EDT StoneX Financial provides access to Chinese commodity markets - StoneX Financial, a subsidiary of StoneX Group, announced that it has become an Overseas Intermediary of the Dalian Commodity Exchange, Shanghai International Energy Exchange, and the Zhengzhou Commodity Exchange, giving it the ability to offer access to key Chinese commodities futures contracts available to international clients. StoneX clients will now have access to these key Chinese commodity markets and the ability to trade internationalised contracts such as the DCE Iron Ore futures, which is one of the most heavily traded metals futures contracts in the world.

08:25 EDT Discovery sees being 'uniquely competitive' with Disney, Netflix - Discovery CEO David Zaslav is speaking at the JPMorgan Global Technology, Media and Communications Conference.

08:23 EDT Osisko Development appoints Marina Katusa to board of directors - Osisko Development is pleased to announce the appointment of Ms. Marina Katusa to its Board of Directors. She is currently a member of the Board of Directors of Silvercorp Metals Inc. and was previously on the Board of Family Services of Greater Vancouver. As part of her appointment to the Board, Ms. Katusa received 27,030 deferred share units in accordance with the DSU Plan of the Company.

08:19 EDT Norwegian Cruise's Regent Seven Seas announces resumption of sailing plan - With Seven Seas Splendor already announced to return in September, Regent Seven Seas Cruises announced its resumption of sailing plan for the rest of The World's Most Luxurious Fleet, which will see all five ships back exploring the oceans by February 2022. The cruise line intends to preserve already published itineraries as much as possible but has also announced newly created sailings in Europe and the Caribbean for Seven Seas Explorer and Seven Seas Voyager. In conjunction with today's announcement, and while considering the global health environment, the cruise line has canceled all sailings up to each ship's respective restart date. Guests with impacted bookings will be contacted directly or via their Travel Advisor. Seven Seas Explorer will welcome back guests on October 16, 2021 sailing from Venice, Italy. She will complete two published Mediterranean voyages before crossing the Atlantic to Miami, Florida and, from November 15, 2021, sail a further two published sailings in the Caribbean. The ship then begins a newly created winter Caribbean season featuring eight new sailings, starting December 20, 2021 with a 14-night Southern Caribbean cruise. After a trans-Atlantic crossing, she will arrive back in Europe on April 10, 2022, sailing three more newly created Mediterranean itineraries before embarking on her published 2022 European summer season on May 14. Seven Seas Mariner will return to sailing on a published December 18, 2021 itinerary, cruising from Miami, Florida to San Francisco, California where she will begin an epic World Cruise on January 5, 2022. Seven Seas Navigator's resumption will begin January 6, 2022 from Miami, Florida with her published 2022 Southern Caribbean winter sailings, which include multiple round-trip Barbados voyages. Seven Seas Voyager returns with five new Mediterranean voyages, the first from Barcelona, Spain on February 15, 2022, before commencing her published 2022 European summer season itineraries exploring the Mediterranean and Northern Europe from April 15, 2022.

08:17 EDT Norwegian Cruise's Oceania Cruises plans return to cruising for four vessels - Oceania Cruises has now announced return to cruising plans for four of its six vessels. Guests on Oceania Cruises will experience a number of OceaniaNEXT enhancements from the first sailing on board Marina when the line resumes operations in August with elevated dining experiences and service levels for guests. OceaniaNEXT enhancements will also debut aboard Regatta, Insignia, Nautica, Riviera, and Sirena as each vessel returns to sailing. Riviera will resume its previously published voyage schedules from Istanbul beginning on October 18, 2021 and sail a series of Mediterranean voyages prior to beginning a winter 2021-2022 series of Caribbean voyages from Miami. Insignia will resume sailing with the December 21, 2021 Panama Canal voyage from Miami prior to embarking on a sold-out 180-day Around The World cruise from Los Angeles to New York. Sirena will commence sailings starting with the January 22, 2022 Caribbean voyage from Miami to Panama City, Panama. In conjunction with today's announcement, the cruise line has canceled all sailings up to each ships' respective restart date. Guests with impacted bookings will be contacted directly or via their Travel Advisor.

08:16 EDT Aptorum Group CEO subscribed shares in the company - Aptorum Group announced that Mr. Ian Huen, Founder, Chief Executive Officer and Executive Director of the Company, through his wholly owned investment company Jurchen Investments Limited, has purchased an aggregate of 1,387,925 Class A Ordinary Shares in the Company at $2.882 per share, representing a 10% premium to the last closing price. "Further to our ALS-4 and SACT-1 updates early this week, I am pleased to say that our leading programs are remaining on track with positive progress," said Mr. Huen. "I believe that my latest subscription demonstrates my steadfast confidence in the Company and I look forward for the Company to continue to deliver the exciting catalysts in 2021 and beyond."

08:13 EDT Kintara Therapeutics provides site activation update on Phase 2/3 GBM trial - Kintara Therapeutics announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research registrational Phase 2/3 clinical trial for glioblastoma multiforme, or GBM, has been activated in 15 U.S. sites as of May 14. The trial is a patient-centered trial for registration evaluating multiple therapies for patients with newly-diagnosed and recurrent GBM. GCAR plans to enroll 150-200 patients in the Kintara arm of the study at 30 sites in the U.S. and Canada with potential to increase this total to 40 clinical trial centers. The trial may accelerate VAL-083's time to pivotal trial completion and potential regulatory submission by up to 18 months. Data from the GBM trial can be used as the foundation for a new drug application and biologics license application submissions and registrations to the FDA and other health authorities. Published pre-clinical and clinical data indicate that VAL-083 has activity against a range of tumor types. VAL-083 has been granted Orphan Drug Designation for GBM by the FDA and EMA and has also been granted Orphan Drug Designations for medulloblastoma and ovarian cancer by the FDA. VAL-083 has not been approved for any indications outside of China.

08:12 EDT Alignment Healthcare's Care Anywhere program serves over 4,000 members - Since launching its Care Anywhere program in 2017, Alignment Healthcare has served more than 4,000 high-risk members suffering from multiple chronic health conditions with unparalleled excellence in virtual care and member satisfaction. With a Net Promoter Score of 76 among its Care Anywhere members, satisfaction nearly doubled that of the industry, which averages a score of 30-40 according to Customer Guru, a commercial provider of member satisfaction tracking services. On average, a Care Anywhere patient is 77 years old, has five to six chronic conditions - from heart failure to diabetes - and monthly institutional health care expenditures in excess of $2,500 prior to their first Care Anywhere visit.

08:10 EDT Wayside Technology's Climb Channel to distribute Io-Tahoe AI data software - Climb Channel Solutions, a wholly-owned subsidiary of Wayside Technology Group, has entered into a distribution agreement with Io-Tahoe to distribute their Data RPA Platform in North America. Io-Tahoe's Data RPA Platform is a no-code AI/ML solution that executes repetitive data processes in an audited, controlled manner. "Data RPA works seamlessly with core systems and existing applications, automating data management, communication and response triggering. Data RPA allows professionals to identify, classify, and remediate data across the entire estate to produce a single version of the truth with the ease of automation," the company said.

08:09 EDT Panbela Therapeutics founder Michael Cullen retires, retains chairman role - Panbela Therapeutics announced that Company founder, Michael Cullen, MD, MBA, retired as an employee of the Company, effective May 25, 2021. Cullen will continue to serve as a member of the Board of Directors and as its Chair. Most recently, Dr. Cullen was Executive Chairman of Panbela's Board of Directors.

08:08 EDT Immutep granted Chinese patent for eftilagimod alpha - Immutep announced the grant of a new patent entitled "Combined Preparations for the Treatment of Cancer" by the Chinese Patent Office. This Chinese patent follows the grant of the corresponding European, Australian, Japanese and United States patents, as announced separately throughout 2019 and 2020. The new patent protects Immutep's intellectual property relating to combination therapy comprising lead active immunotherapy candidate eftilagimod alpha, which is a LAG-3 fusion protein, and a chemotherapy agent. The chemotherapy agent is oxaliplatin, carboplatin, or topotecan, and the patent provides protection in the territory of mainland China. The new patent is owned by Immutep S.A.S. and exclusively licensed to Immutep's partner in China, EOC Pharma. The patent expiry date is 19 December 2034.

08:07 EDT Norwegian Cruise announces plans for eight additional ships to relaunch in Fall - Norwegian Cruise Line Holdings announced the next phase of its planned resumption of cruising across its three cruise lines. Norwegian Cruise Line announced plans for eight additional ships to relaunch beginning Fall 2021. Oceania Cruises will resume cruise operations with three additional ships, Riviera, Insignia, and Sirena, between October 2021 and January 2022. Regent Seven Seas Cruises will see all five ships back exploring the oceans by February 2022. Voyages expected to operate in the U.S. are contingent on obtaining a Conditional Sailing Certificate from the U.S. Centers for Disease Control and Prevention. All initial voyages will operate with fully vaccinated guests and crew in addition to the Company's robust, multi-layered SailSAFE health and safety program. Norwegian Cruise Line has announced further details on its phased voyage resumption plan for additional ships beginning Fall 2021. Earlier this week the line announced its plan for a return to cruising in the U.S. with sailings in Alaska starting August 7, 2021 contingent on CDC authorization. Newly announced expected redeployment plans include the following: Norwegian Joy will cruise from Miami beginning October 19, 2021 with five to 11-day Caribbean voyages. Norwegian Breakaway will cruise seven-day itineraries to Bermuda from New York beginning October 24, 2021. Pride of America will offer seven-day Hawaii interisland voyages from Honolulu beginning November 6, 2021. Norwegian Bliss will cruise from Los Angeles for seven-day Mexican Riviera voyages beginning November 7, 2021. Norwegian Encore will offer seven-night itineraries from Miami to the Caribbean beginning November 14, 2021. Norwegian Escape will cruise seven-day itineraries to the Caribbean from Orlando, Florida beginning November 20, 2021. Norwegian Pearl will sail from Miami offering Panama Canal, Bahamas and Caribbean cruises beginning December 23, 2021. Norwegian Jewel will offer Panama Canal cruises from Panama City and New York beginning January 20, 2022. Norwegian Sun will sail a five-day Japan itinerary from Hong Kong beginning January 28, 2022, before sailing a variety of 11-day cruises from Hong Kong, Singapore and Bangkok. Norwegian Spirit will cruise 12-day Australia and New Zealand voyages from Sydney, and Auckland, New Zealand beginning February 9, 2022. Due to the previously disclosed lead time needed to relaunch a vessel and in order to maximize the short Alaska cruise season, the cruise line has made the decision to transfer crew from Norwegian Joy to Alaska and has canceled itineraries aboard Norwegian Joy from Montego Bay, Jamaica from August 7 through October 9, 2021. In addition, certain sailings outside of these newly announced voyages have been canceled. Impacted guests on voyages that will not operate will be notified accordingly.

08:05 EDT Lipocine patent claims found invalid by Court in Clarus Therapeutics litigation - Lipocine announced that the District Court for the District of Delaware has granted Clarus Therapeutics' motion for Summary Judgment, finding the asserted claims of Lipocine's U.S. patents 9,034,858; 9,205,057; 9,480,690; and 9,757,390 invalid for failure to satisfy the written description requirement of 35 U.S.C. Section 112. Clarus still has remaining claims before the Court. "We are extremely disappointed in the court's decision and believe the ruling is contrary to the established law of Section 112. We continue to believe in the strength and validity of our intellectual property," said Lipocine CEO Dr. Mahesh Patel. "We are in the process of evaluating the court's decision and determining next steps."

08:04 EDT Ford establishing 'Ford Pro' vehicle services and distribution business

08:03 EDT Allscripts announces $350M share repurchase program - Allscripts announced that its board of directors has approved a new share repurchase program under which Allscripts may purchase up to $350M of its common stock. The new share repurchase program does not have a termination date. The new share repurchase program replaces the previously existing share repurchase program, which authorized Allscripts to repurchase $300M of its common stock through December 31. Allscripts repurchased the entire amount available under the prior program.

08:02 EDT Bed Bath & Beyond partners with DoorDash on same day delivery service in U.S. - Bed Bath & Beyond (BBBY) announced that it has strengthened its Same Day Delivery services in the U.S. through a partnership with DoorDash (DASH), making it easier and more convenient than ever to shop online for products from Bed Bath & Beyond and buybuy BABY. Same Day Delivery service will be powered through DoorDash Drive - DoorDash's white-label fulfillment platform that powers direct delivery for any business. The DoorDash launch arrives right on time to shop essentials, must-haves, and amazing deals ahead of the Memorial Day holiday. Through DoorDash Drive, Bed Bath & Beyond and buybuy BABY websites will expand same day delivery to over 3,000 additional zip codes across the country. With the added coverage same day delivery is now available in 99% of their store locations and allows customers the convenience to shop an array of different delivery options. Customers can utilize the service by going to bedbathandbeyond.com and buybuybaby.com and selecting the option for Same Day Delivery at checkout. Once the order is placed, a Dasher will pick up the items at the local store and deliver them to the customer's home via contactless delivery. Customers are also now able to place an order just hours before closing and still receive it the same day and track packages live.

08:01 EDT BGC Partners selling Insurance Brokerage business for $500M to Ardonagh Group - BGC Partners has entered into an agreement to sell its Insurance Brokerage business for $500M of cash consideration to The Ardonagh Group. The companies expect to use the proceeds to accelerate Fenics growth and to repurchase shares and/or units. The Insurance Brokerage business provided $191M, or less than 10%, of BGC's total revenue over the trailing twelve-months. The sale proceeds will provide additional capital to accelerate Fenics growth, which increased 40% year-over-year in Q1. The transaction is expected to close in 2H21. The one-time gain associated with the transaction will be reflected in BGC's consolidated results under GAAP but will be excluded from results for Adjusted Earnings. BGC intends to use the proceeds from the sale to invest in its Fenics business, to repurchase BGC shares and/or units, and for general corporate purposes.

07:51 EDT NFI Group receives order for 100 additional transit buses - NFI Group announced that the Washington Metropolitan Area Transit Authority has exercised options for 100 additional forty-foot Xcelsior heavy-duty transit buses from NFI's U.S. subsidiary New Flyer of America. The options are being exercised from New Flyer's backlog in the third year of a five year contract originally awarded in 2018.

07:48 EDT KemPharm announces Orange Book listing for six patents for serdexmethylphenidate - KemPharm announced that six U.S. patents governing serdexmethylphenidate, KemPharm's prodrug of d-methylphenidate, and AZSTARYS, are now listed in the Food and Drug Administration publication, "Approved Drug Products with Therapeutic Equivalence Evaluations," commonly known as the "Orange Book." In addition, the Orange Book listing confirms the status of SDX, which is the primary API in AZSTARYS, as a new chemical entity, which provides at least five years of market exclusivity. AZSTARYS was conditionally approved by the FDA in March 2021 as a once-daily product for the treatment of attention deficit hyperactivity disorder in patients age six years and older. Recently, SDX was classified as a Schedule IV controlled substance by the Drug Enforcement Administration and thereby formally approved for marketing in the U.S. SDX is the primary API in KP484, an investigational ADHD treatment, and the only API in KP879, an investigational treatment for stimulant use disorder. Among the listed patents, U.S. Patent No. 9,079,928, due to expire on July 27, 2032, is a composition of matter patent. The other five patents are all slated to expire on December 9, 2037 and include U.S. Patent No. 10,584,112 and U.S. Patent No. 10,584,113, U.S. Patent No. 10,759,778, U.S. Patent No. 10,858,341 and U.S. Patent No. 10,954,213. All or some of these patents may be subject to patent term extension. The Orange Book listing confirms that SDX, which is contained within AZSTARYS, is an NCE, which provides five years of market exclusivity that expires on May 7, 2026.

07:45 EDT ContraFect announces multiple publications on exebacase - ContraFect announced the publication on the administration of exebacase, arthroscopically, in the setting of debridement, or the surgical removal of the infected tissue, in patients with relapsing multidrug resistant Staph epidermidis PKI in Frontiers in Medicine. The company also announced two additional publications of a novel method for the clinical determination of the susceptibility of Staphylococci to exebacase for use in the clinical setting. In this manuscript, four patients ages 79 to 89 years with significant comorbidities received intra-articular administration of exebacase. All had undergone several previous prosthetic knee revisions. Three had relapsing PKI despite suppressive antibiotics, following open debridement and implant retention. Two had clinical signs of septic arthritis; the two others had sinus tracts. All patients were infected only by S. epidermidis that expressed different drug susceptibilities over time. After over one year of follow-up, two patients had a favorable clinical outcome with the disappearance of clinical signs of septic arthritis, providing encouraging preliminary evidence supporting the potential activity of exebacase in this highly treatment resistant patient group. The safety profile was favorable and there were no serious adverse events deemed to be associated with treatment. The Company continues to provide early access to exebacase to individual named patients with chronic post-operative PJIs under ATUs and is evaluating further investigation of exebacase for the treatment of PJIs. ContraFect published two additional exebacase manuscripts. In the Antimicrobial Agents and Chemotherapy where the publication was selected by the journal as an 'Editor's Pick', laboratory data demonstrate the accurate and reproducible assessment of microbial susceptibility to exebacase. The Journal of Clinical Microbiology published laboratory data to establish new standards of susceptibility testing to evaluate the in vitro activity of exebacase against Staph aureus.

07:44 EDT Jushi Holdings appoints Marina Hahn to board of directors - Jushi Holdings (JUSHF) announced that Marina Hahn has been appointed to its Board of Directors effective immediately. Hahn has spent the last several years as VP, Co-Founder of New Business at ZX Ventures, the growth arm of Anheuser-Busch (BUD).

07:42 EDT CMX announces $50M Series A investment led by Morgan Stanley Expansion Capital - CMX announced it has completed an investment led by Morgan Stanley Expansion Capital. The financing will be used to accelerate the company's growth by enabling CMX to expand its team and product offerings and execute its vertical market expansion strategy. Using automation, data, visibility, and insights, the CMX1 platform enables food, retail, hospitality, and service organizations to digitally transform quality, risk, safety, and compliance-focused programs. The platform empowers organizations to protect brand reputation, maintain customer trust, and drive operational performance across their locations.

07:41 EDT Terazo secures funding from Twilio, Tercera - Terazo, a software development and managed services firm, announced it has closed a funding round of $10M+. The round was led by Tercera, a growth-focused investment and advisory firm specializing in cloud professional services, with participation from Twilio. Terazo is a member of Twilio's partner program.

07:39 EDT Dick's Sporting sees FY21 gross CapEx $370M-$395M, net CapEx $300M-$325M

07:37 EDT Dick's Sporting jumps 6% to $89.48 after Q1 results beat, FY21 guidance raised

07:36 EDT Sunrise Credit Union adopts nCino platform to improve member experience - nCino announced that Manitoba's Sunrise Credit Union is live on the nCino Bank Operating System. "Sunrise will now be able to offer a user-friendly, digital on-line and in-branch Deposit Account Opening experience members today expect through the nCino platform. The nCino platform will be able to significantly reduce the time required to open new memberships and new accounts, allowing Sunrise employees the ability to spend an increased amount of personal time with their members to understand their financial needs and provide a first-class customer experience," the company said. In addition to utilizing nCino's Deposit Account Opening solution, Sunrise has also purchased nCino's Commercial Banking, Retail Banking and Residential Mortgage solutions which it plans to roll-out in phases to help further automate tasks.

07:34 EDT Canadian National, Kansas City Southern jointly file for voting trust approval - Canadian National (CNI) and Kansas City Southern (KSU) announced that they have taken the next step on their path to combine. CN and KCS jointly filed with the Surface Transportation Board, or STB, a renewed motion for approval of its voting trust that outlines the case for approval of the voting trust to advance the CN-KCS merger. As part of the application, CN is committing to divesting KCS' 70-mile line between New Orleans and Baton Rouge, which is less than 0.7% of the approximately 27,000 route-miles the two companies operate. This commitment eliminates the sole area of overlap between the CN and KCS networks, thereby making the combination an end-to-end transaction. Under CN's proposed voting trust, KCS would maintain complete independence. KCS will continue to be managed by its existing management and board of directors, with a trustee who is a former chief executive of KCS. KCS will remain intact and preserve its ability to pursue its independent business objectives. CN will have no influence over the day-to-day management or operation of KCS.

07:33 EDT Beyond Air reaches settlement agreement with Circassia for LungFit PH - Beyond Air announced an agreement with former LungFit PH commercial licensee, Circassia Group. Under the terms of the agreement, Beyond Air retains United States and China commercialization rights to LungFit PH in exchange for returning upfront and milestone payments received by the company in 2019, along with capped future royalty payments. Beyond Air now holds full global rights to LungFit PH. Beyond Air will repay Circassia the $10.5M received in 2019 over a two-year period commencing after the LungFit PH receives United States Food and Drug Administration approval. Payments will be made as follows: $2.5M upon FDA approval, $3.5M one year after FDA approval, and $4.5M two years after FDA approval. Additionally, beginning in year three post-approval, Circassia will receive a quarterly royalty payment equal to 5% of LungFit PH net sales in the US. This royalty will terminate once the aggregate payment reaches $6 million. As of April 30, 2021 Beyond Air had approximately $34.9M in cash, cash equivalents and marketable securities. Expected quarterly spend remains at approximately $5M, exclusive of settlement related payments.

07:30 EDT ADC Therapeutics announces results from camidanlumab tesirine study published - ADC Therapeutics announced that results of the Phase 1 clinical trial of camidanlumab tesirine, or Cami, an anti-CD25 ADC, in patients with relapsed or refractory Hodgkin and non-Hodgkin lymphomas have been published online in The Lancet Haematology. The multicenter, open-label, single-arm, dose escalation and dose expansion Phase 1 clinical trial enrolled 133 adult patients, 77 with classical Hodgkin lymphoma and 56 with non-Hodgkin lymphoma. Enrolled patients were required to have pathologically confirmed relapsed or refractory Hodgkin lymphoma or non-Hodgkin lymphoma and no therapies with established clinical benefit for their disease stage available to them. In the total patient population, the overall response rate, or ORR, was 58%, with 38 of 130 patients reported to have a complete response. In heavily pretreated patients with Hodgkin lymphoma, across all doses, the ORR was 71%, with 32 of 77 patients reported to have a complete response. In Hodgkin lymphoma patients who received 45 microgram/kg, the ORR was 86%, with 18 of 37 patients reported to have a complete response. In Hodgkin lymphoma patients who received 30 microgram/kg, the ORR was 55%, with seven of 20 patients reported to have a complete response. In patients with non-Hodgkin lymphoma, the ORR was 38%, with five of 53 patients reported to have a complete response. The overall median duration of response was 6.6 months for all patients with Hodgkin lymphoma and 7.2 months for Hodgkin lymphoma patients who received 45 microgram/kg. Cami demonstrated an acceptable safety profile. The most commonly observed adverse events included elevated liver enzymes, rash, fatigue, oedema or effusion, and nausea. Based on the data from this Phase 1 clinical trial, a Phase 2 trial to further evaluate the safety and efficacy of Cami in patients with relapsed or refractory Hodgkin lymphoma is ongoing. Interim data from the pivotal Phase 2 trial presented at the 2020 American Society of Hematology meeting demonstrated encouraging antitumor activity as a single agent with an ORR of 83%, a complete response rate of 38% and no new safety signals. These data highlight the potential for Cami to address an unmet need in heavily pretreated patients.

07:28 EDT Gol Linhas sees Q2 revenue R$1B - Sees Q2 EBITDA R$0.1B. Sees Q2 CapEx R$0.1B. The company has fully repaid the $250M short term loan it received in August 2020. Sees Q2 total ASK 4.2B. Raises Q2 load factor view to 81% vs. 79%. "The successful completion of the vaccination roll out expected in Brazil this year, combined with our already improved cost base and stronger balance sheet, gives us confidence in our performance for the second half of 2021. We will also benefit from a reduced fleet cost for the next decade as we take more deliveries of the 737 MAX aircraft that will compose a significant part of the GOL fleet," said CEO Paulo Kakinoff. "These strengths will enable GOL to capitalize on the many growth and expansion opportunities that are now available in our markets, enabling us to benefit from a strong rebound in demand for travel as we move into the Southern Hemisphere's Summer season. We are committed to delivering profitable growth in an environmentally sustainable manner with less fuel consumption and lower CO2 emissions per passenger while, at the same time, improving GOL's industry leading customer experience."

07:16 EDT Gilat Satellite extends multi-million dollar IoT project in Latin America - Gilat Satellite Networks announced the extension of its multi-million dollar IoT project in Latin America. Tier-1 MNO extends coverage of Gilat's cellular backhaul solution as it expands its Agriculture IoT network. "The Agribusiness IoT market addresses a critical need to better provide communication between the field and the office. Gilat provides the 4G network expansion to support the growing business with connectivity of machines that require real-time control and monitoring of harvesters and agricultural tractors. This ensures cost-effective decisions, better crop management and greater speed, efficiency and productivity in the production flow," the company said.

07:13 EDT Applied Genetic appoints Janet Rae as SVP, global regulatory and quality - Applied Genetic Technologies (AGTC) announced the appointment of Janet Rae, RAC, as SVP of Global Regulatory and Quality. The appointment of Ms. Rae, who will join AGTC on June 18, 2021, is an important step in the Company's strategy to prepare for anticipated late-stage development of its X-Linked Retinitis Pigmentosa and Achromatopsia programs. She will be instrumental in assuring regulatory compliance as the Company initiates its previously announced plans to lease a build-to-suit 21,000 square foot current Good Manufacturing Practices manufacturing and quality control facility adjacent to its Florida facility. Most recently, she served as Vice President, Head of Regulatory Affairs for Gene Therapy at Ultragenyx Pharmaceutical (RARE).

07:12 EDT RedHill Biopharma granted patent applications for COVID-19 treatment candidates - RedHill Biopharma received two Notices of Allowance from the USPTO covering opaganib and RHB-107 as methods for the treatment of COVID-19 caused by the SARS-CoV-2 virus. Both opaganib and RHB-107 are novel COVID-19 therapeutic candidates, in oral pill form, with dual mechanism of action effects. Both are host-targeted and are therefore expected to be effective against emerging viral variants with various mutations in the spike protein. Enrollment in opaganib's global Phase 2/3 study in hospitalized patients with severe COVID-19 is almost 100% complete. RHB-107's Phase 2/3 study is ongoing in non-hospitalized patients with symptomatic COVID-19 who do not require supplemental oxygen. Together, this covers potential treatment for the vast majority of affected patients. In view of the upcoming completion of enrollment, RedHill is evaluating the regulatory path for opaganib with a focus on those countries currently most affected by COVID-19. Additional studies to support the potential of such applications and the use or marketing of opaganib are likely to be required.

07:11 EDT Arko Corp. enters extended wholesale agreement with Core-Mark - GPM Investments, a wholly owned subsidiary of ARKO Corp. (ARKO) and Core-Mark Holding Company (CORE), announced the signing of an extended 32-month master supply agreement with Core-Mark International, Inc. as part of a consolidation of the company's wholesalers and continued growth strategy. The agreement will increase the number of GPM store locations for which Core-Mark provides service from 865 to 1,055. Under the supply agreement, Core-Mark agreed to provide transition services to facilitate the transfer of services from certain of GPM's previous wholesalers. Core-Mark will also continue offering support services for GPM's imports and specialty products program. Core-Mark will continue to be GPM's largest single supplier, distributing products across 29 different categories to its portfolio of approximately 1,400 stores.

07:08 EDT Anavex appoints Jiong Ma to board of directors - Anavex Life Sciences announced the appointment of Ms. Jiong Ma, PhD to its Board of Directors. As a Partner at Braemar Energy Ventures, Ms. Ma focused on investments in digitization of industry, resource efficiency, mobility, renewable energy infrastructure, and deeptech. Elliot Favus will retire as a Board member.

07:07 EDT Cybin files international patent application with over 153 global jurisdictions - Cybin announced that it has filed an international patent application that brings the potential to obtain patent coverage in 153 countries. The application, governed by the Patent Cooperation Treaty grants the Company the right to file future national applications into treaty member jurisdictions, including important potential markets for the Company. The PCT claims a library of psychedelic derivative drug development candidates. The Company continues to execute upon its three-pillar drug development strategy to create: (a) a novel drug discovery platform and research on the potential efficacy of psychedelic molecules to address unmet mental health needs; (b) efficient drug delivery to enhance dosing control; and (c) a potential novel treatment regimen. The PCT application is intended to provide broad international patent protection of key intellectual property in support of the Company's strategic objectives. "Technologies gained by Cybin resulting from our strategic acquisition of Adelia Therapeutics, coupled with subsequent research initiatives from our experienced scientific team, have produced Cybin's first PCT filing. As we progress our R&D and clinical programs, we expect to continue to create and develop innovative therapeutics with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods, and reduced side effects," stated Doug Drysdale, Chief Executive Officer of Cybin.

07:06 EDT C4 Therapeutics to advance CFT8919 to IND-enabling studies - C4 Therapeutics announced that it has decided to advance CFT8919, a novel degrader of epidermal growth factor receptor in non-small cell lung cancer, into investigational new drug, or IND,-enabling studies and anticipates filing an IND for this program by mid-2022, with the goal to initiate a Phase 1/2 clinical trial by year-end 2022. The preclinical data C4T will present at the upcoming Keystone Symposium establish CFT8919 as a potent and selective degrader of EGFR L858R that is based on an allosteric EGFR binding motif. As a single agent, CFT8919 is active in both in vitro and in vivo models of EGFR L858R-driven NSCLC without resistance-causing secondary mutations in EGFR, as well as in similar models that harbor secondary resistance mutations such as EGFR T790M and C797S. Additionally, CFT8919 demonstrates intracranial activity, indicating that it has the potential to treat brain metastases. Together, these data suggest CFT8919 may be active, as single agent, in patients with resistance to EGFR inhibitors due to secondary mutations in EGFR, including T790M and C797S, as well as in the front-line setting with the potential to avoid the emergence of resistance-causing secondary EGFR mutations seen with currently approved EGFR inhibitors. Progress to 2021 Key Milestones: Initiate patient dosing for CFT7455 in 1H 2021; Submit an IND application for CFT8634 in 2H 2021; Advance the BRAF program into IND-enabling studies in 2021; Continue lead optimization activities for the RET program through 2021.

07:04 EDT Riot Blockchain, Marathon Digital up over 3% as Bitcoin, cryptocurrencies rally - In early pre-market trading, shares of Riot Blockchain (RIOT) are up over 4% at $26.20 and Marathon Digital (MARA) are up 3.3% at $23.36 as the overnight price of Bitcoin hit its highest level since Friday above $40,800. Shares of Coinbase (COIN) are also up 1.7% at $246.59.

06:57 EDT Suncor updates corporate strategy for net-zero emissions by 2050 - Suncor will share its updated strategy focused on increasing shareholder returns and accelerating its progress in reducing GHG emissions with an objective to be net-zero by 2050. Suncor will focus its planned $5B annual capital spend through 2025 on optimizing its integrated value chain and sustaining the base business, while improving its cost and carbon competitiveness, and growing low-carbon businesses, which is expected to deliver an annual $2B of incremental free funds flow to the business by 2025. This planned free funds flow growth will be focused on returning value to shareholders through increased dividends, ongoing share buybacks and fortifying the balance sheet through continued debt reduction. In addition, the strategy includes a goal to be a net-zero GHG emissions company by 2050 and contribute to society's net-zero goals. By 2030, Suncor expects to reduce greenhouse gas emissions by 10 megatons per year across its energy value chain. The company's emissions were approximately 29 MT per year in 2019. Suncor plans to accomplish this by reducing emissions in its base business and at the same time growing its renewable fuels, electricity, and hydrogen businesses.

06:53 EDT Becton Dickinson announces U.S. launch of Urine Culture Application - Becton Dickinson announced the U.S. launch of a Urine Culture Application for use with the BD Kiestra lab automation incubation and imaging system that can transform the way microbiology labs approach urine culture analysis.

06:47 EDT Tritium to go public through Decarbonization Plus Acquisition Corp. II merger - Tritium, a Brisbane-based developer and manufacturer of direct current, or DC, fast chargers for electric vehicles, or EVs, and Decarbonization Plus Acquisition Corporation II (DCRN) announced a definitive agreement for a business combination that would result in Tritium becoming a publicly listed company. Upon closing of the transaction, the combined company will be named Tritium and is expected to be listed on the Nasdaq and trade under the new ticker symbol (DCFC). Tritium has provided more than 2.7M high-power charging sessions across 41 countries, delivering over 55 GWh of energy. The company's intellectual property includes the only fully liquid-cooled, IP65-rated charger, providing customers with technology that is ingress-protected and sealed from outside elements, thus reducing the total cost of ownership. The transaction is anticipated to generate gross proceeds of up to approximately $403M of cash, assuming minimal redemptions by DCRN's public stockholders. The funds will be used to fund operations and growth. The pre-money enterprise value of the combined company is $1.4B at the price of $10 per share, excluding cash to go to the balance sheet. Jane Hunter will continue as the CEO of Tritium, alongside co-founders James Kennedy and executives David Toomey and Michael Hipwood. The boards of directors of both Tritium and DCRN have approved the proposed transaction, subject to, among other things, the approval by DCRN's stockholders and satisfaction or waiver of the other conditions stated in the definitive documentation, including the waiver or expiration of a Tritium shareholder's right to acquire Tritium under the shareholder's deed in relation to Tritium.

06:38 EDT Centogene nominates Rene Just as CFO - Centogene nominated Rene Just as CFO, which will be proposed to the shareholders at the upcoming Annual General Meeting. Rene will join the company on June 1 to work closely through the transition with current CFO Richard Stoffelen, who has decided to leave the company as of June 30. Before joining Centogene, Just was the Group CFO at Riemser Pharma Holding, previously owned by the private investment and private equity firm Ardian.

06:36 EDT Henry Schein awarded $53.4M SNS contract for PPE storage, distribution - Henry Schein announced that the company was awarded a $53.4M contract from the U.S. Department of Health and Human Services for the storage and distribution of 80,000 pallets of personal protective equipment and COVID-19 related products to support the Strategic National Stockpile, part of the Office of the Assistant Secretary for Preparedness and Response within HHS. This agreement will further the efforts of ASPR to leverage the collective strengths of both the public and private sectors to maximize the breadth of coverage and capabilities, minimize vulnerabilities, and facilitate an expedited response to public health crises and other emergencies.

06:35 EDT Emergent BioSolutions reports 'positive' data from Phase 2 CHIKV VLP study - Emergent BioSolutions announced two-year persistence data from its Phase 2 clinical study evaluating the safety and immunogenicity of the company's investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate in 415 healthy adults. Emergent's CHIKV VLP vaccine, the only single-dose VLP-based vaccine currently in clinical development for active immunization against chikungunya disease, continued to demonstrate a favorable safety profile and had generated a dose-related increase in neutralizing antibody response against the chikungunya virus as previously reported. Two years post-vaccination, SNA responses were 19 times higher than pre-vaccination titers following a single adjuvanted 40 microgram dose of the CHIKV VLP vaccine, supporting the persistence of the immune response. All subjects in the single-dose regimen remained seropositive at their one-year and two-year visits. The vaccine candidate was well-tolerated and no significant vaccine-related safety concerns were identified. The majority of solicited adverse events were mild or moderate in severity and the most frequent was local injection site pain.

06:04 EDT Magnite changes leadership team after SpotX acquisition - Magnite announced changes to its executive leadership team, effective July 1. These are the company's first major steps towards integrating its recent acquisition of SpotX. SpotX's former Chief Technology Officer, J. Allen Dove, will serve as CTO of Magnite; Adam Soroca, Head of Magnite's Global Buyer Team, will be moving into a newly created role as Chief Product Officer; Sean Buckley, SpotX's former COO, will become Chief Revenue Officer for CTV, and Joe Prusz will serve as the Chief Revenue Officer for Magnite's online video and display business, known as DV+. SpotX's former CEO, Mike Shehan, will continue with Magnite as a consultant through the end of the year. Additionally, Tom Kershaw, who served as Magnite's Chief Technology Officer for the past four years, will be stepping down to pursue a new opportunity outside of ad tech. Magnite's executive leadership team will be comprised of the following members, reporting to President & CEO, Michael Barrett: CFO David Day; COO Katie Evans; CTO J. Allen Dove; Chief Product Officer Adam Soroca; Chief Revenue Officer, CTV: Sean Buckley; Chief Revenue Officer, DV+: Joe Prusz; Chief Strategy Officer: Erik Hovanec; Chief Marketing Officer: David Hertog; Chief People Officer and Chief Accounting Officer: Shawna Hughes; General Counsel: Aaron Saltz.

05:50 EDT LexinFintech CFO Craig Yan Zeng to resign - LexinFintech announced that Craig Yan Zeng has tendered in his resignation as the CFO, effective on June 7. Kris Qiao Qian, Lexin's chief financing cooperation officer, has been appointed as the acting CFO. Zeng's resignation from his position was due to personal reasons, and he will remain as a director of the board of directors of the company and also serve as a senior consultant to the company following his resignation. The company has initiated a search for a permanent CFO. In addition, Zeng will continue to serve as the CFO for Lexin's next earnings report for Q1 and will supervise and sign off the review of the upcoming unaudited financial results.

05:39 EDT Buyer consortium issues statement on Hollysys recent quarterly results - A buyer consortium consisting of Shao Baiqing, Ace Lead Profits and CPE Funds Management commented on recent financial information released by Hollysys. the consortium said, "On May 13, 2021, Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) (the "Company") disclosed financial condition and results of operations for the quarter and the nine-month period ended March 31, 2021, together with its review and analysis of the comparable periods for fiscal year 2020. The Company intended to "highlight" selected financial metrics by making comparisons to the low base numbers for the first three months of 2020, when the Company's performance was severely and negatively affected by COVID-19, and sought to convince the public that the Company is on the right track under the current management. But a close look at these data, in particular by comparing them to 2019 pre-pandemic results, reveals significantly deteriorating financial and operational conditions of the Company since the sudden removal of previous management in July 2020... The Company's closing price on May 25, 2021 was $13.38, significantly lower than the $17.10 offer price provided in the proposal (the "Proposal") by the buyer consortium consisting of Mr. Shao Baiqing, Ace Lead Profits Limited and CPE Funds Management Limited (the "Consortium"). The Consortium believes that the Company's operations and financial conditions will further weaken because existing management and the board of directors do not know how to run the Company successfully. The Company's struggling operations, the general negative sentiment towards U.S.-listed Chinese companies and the associated risk of forced delisting, the very low trading volume of the Company shares, and the highly attractive offer price are some of the many compelling reasons why the board should immediately engage with the Consortium and convene a shareholder meeting for the shareholders to consider and vote on the Proposal. The board should also take all necessary corporate action to render the shareholder rights plan inapplicable to the Proposal as the Proposal offers all shareholders, other than the Consortium, with a compelling premium in a fair and equal manner and is not the type of takeover that the rights plan intends to prevent. Short of those actions, the board would find themselves at great risk of further violating their fiduciary duties to the shareholders. With the Company's condition worsening quarter by quarter, the board is presented with ever increasing urgency to act on the Proposal immediately."

05:31 EDT Amazon Web Services to open infrastructure region in the UAE in 2022 - Amazon Web Services, or AWS, an Amazon.com company, announced that it plans to open an infrastructure region in the United Arab Emirates, or UAE, in the first half of 2022. The new AWS Middle East Region will consist of three availability zones and become AWS's second region in the Middle East with the existing AWS Region in Bahrain. Globally, AWS has 80 availability zones across 25 geographic regions, with plans to launch 18 more availability zones and six more AWS Regions in Australia, India, Indonesia, Spain, Switzerland, and the United Arab Emirates.

05:16 EDT Dada Nexus to be included in MSCI ACWI Index - Dada Group announced that it will be included in the MSCI ACWI Index, effective after the U.S. market close on May 27. MSCI Inc., a provider of research-based indexes and analytics, announced this inclusion in its May Semi-Annual Index Review.

05:11 EDT Ambarella, Lumentum and ON Semiconductor collaborate on AIoT device deployment - Ambarella (AMBA), Lumentum (LITE) and ON Semiconductor (ON) announced two new joint reference designs that accelerate AIoT device deployment across verticals, building on the companies' previous joint solution for contactless access systems. By combining the data from Lumentum's VCSEL array illuminators and an ON Semiconductor image sensor using Ambarella's AI SoC, the companies said higher levels of accuracy and more intelligent decision-making can be achieved in next-generation AIoT devices for biometric access control, 3D electronic locks and other intelligent sensing applications. Originally intended for biometric access control and electronic locks, these new reference designs can also address the needs of smart cities, smart buildings, smart homes and intelligent healthcare. The open software development kit, or SDK, for Ambarella's CVflow AI vision processors allows the easy integration of third-party applications while enabling OEMs to address differing regional requirements with a single platform. These joint reference designs and development kits are expected to be available in June.